Search Results for: avdx

Avant Diagnostics, Inc. (OTCQB: AVDX) is a medical technology company that focuses its efforts on the human genome project. This genetic research continues to delve deeper into identifying variations of specific genes in the genome. A genome is all of the genes that make up a cell or organism. It’s basically a recipe book on … Continue reading “Avant Diagnostics, Inc. (AVDX) Aims to Cut Costs and Deliver Fast Results with Ovarian Cancer Detection Test”

Ovarian cancer is the fourth-leading cause of cancer deaths among women in the U.S. When someone is diagnosed with ovarian cancer, they are usually in the advanced stages of the disease and treatment is not nearly as effective as it would be if it had been discovered earlier. Avant Diagnostics, Inc. (OTCQB: AVDX) is a … Continue reading “Avant Diagnostics, Inc. (AVDX) Participating in the ‘War on Cancer’ With Preventative Early Detection Technology”

Earlier today, Avant Diagnostics, Inc. (OTCQB: AVDX) announced that it will present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference, which will take place at The Ritz-Carlton in Miami on South Beach on February 22, 2016. As a presenter, Avant will be provided with a 30-minute time slot with which to … Continue reading “Avant Diagnostics, Inc. (AVDX) Presenting at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference”

The recent announcement by Avant Diagnostics, Inc (OTCQB: AVDX) and Amarantus Bioscience Holdings, Inc (OTCQX: AMBS) of their intention to tie the knot is a message of cheer for women who may be at risk for ovarian cancer. It also promises a partnership that will aggressively pursue opportunities in the rapidly expanding molecular diagnostics (MDx) … Continue reading “Avant Diagnostics (AVDX) Announces a Partnership of Promise with Amarantus Diagnostics”

The American Cancer Society estimates that in 2016, about 22,280 new cases of ovarian cancer will be diagnosed and 14,240 women will die of ovarian cancer in the U.S. Mortality rates for ovarian cancer have declined only slightly in the forty years since the “War on Cancer” was declared. However, other cancers have shown a … Continue reading “Avant Diagnostics (AVDX): Early Detection of Ovarian Cancer Increases Survival Rates by Five Times”

Late last month, Avant Diagnostics, Inc. (OTCQB: AVDX) made headlines when it announced plans to merge with Amarantus Diagnostics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS). Under the terms of the previously announced Letter of Intent, Avant will issue 80 million shares of common stock to Amarantus upon execution of definitive merger … Continue reading “Avant Diagnostics, Inc. (AVDX) Positioned to Expand Clinical Pipeline following Entry into Letter of Intent to Merge with Amarantus Diagnostics”

Ovarian cancer is a deadly disease and should be taken seriously. Early detection and monitoring of tumor development is the key to survival. If someone gets tested regularly and detects ovarian cancer early, their five-year survival rate can be as high as 93 percent, compared to a five-year survival rate of only 18 percent if … Continue reading “Avant Diagnostics (AVDX): Battling Ovarian Cancer with Its Early Detection OvaDx Test”

Recently, in Avant Diagnostics set to exploit new opportunities in the laboratory testing market (http://dtn.fm/hg8TK), we reported that ‘OvaDx is now undergoing 510K trials.’ It seems we jumped the gun. We reached out to Avant’s CEO, Gregg Linn, to get clarification on our report and he confirmed that the OvaDx approval process hasn’t reached the … Continue reading “Avant Diagnostics (AVDX): Trials and Tribulations”

According to recent analysis out late last year from the world’s second largest publisher of premium market reports, MarketsandMarkets, the global market for biomarkers is on-track to grow at a CAGR of 13.58 percent through 2020, reaching upwards of $45.55 billion on the strength of increasing healthcare, as well as R&D spending. A key driver … Continue reading “Avant Diagnostics, Inc. (AVDX) Ovarian Cancer Early Detection Diagnostic Tech Bolstered Mightily By Amarantus Bioscience Merger”

Earlier today, Avant Diagnostics, Inc. (OTCQB: AVDX) announced that it has entered into a non-binding letter of intent to merge with Amarantus Diagnostics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS). Under the terms of the agreement, Avant will issue 80 million shares of common stock to Amarantus upon execution of definitive agreements, … Continue reading “Avant Diagnostics, Inc. (AVDX) Announces Letter of Intent to Merge with Diagnostics Division of Amarantus Bioscience Holdings, Inc.”